Answers are grounded in this paper and cite their sources.
Demonstrates enhanced antibody responses in murine models using conjugate vaccine technology, indicating potential for improved flu vaccines.
Influenza remains a major public health concern due to its high mutation rate and the limited efficacy of current seasonal vaccines. Traditional subunit and inactivated virus vaccines often elicit strain-specific responses and fail to generate long-lasting or broadly protective immunity. To address these limitations, we utilized the iBoost platform, a conjugate vaccine strategy based on a chimeric designer peptide (CDP) derived from bacterial immunogens, to enhance immune responses against influenza virus antigens. Using hemagglutinin (HA) and neuraminidase (NA) constructs from the A/Wisconsin/588/2019 (H1N1) strain, we developed CDP-H1 and CDP-N1 vaccine candidates and assessed their immunogenicity in murine models. Compared to unconjugated counterparts, CDP-fused constructs induced significantly stronger and more rapid antibody responses, with broader IgG subclass distribution and higher IgG2a levels, potentially indicative of enhanced effector functions. CDP-H1 elicited measurable HA-inhibiting activity by hemagglutination inhibition (HAI) assay and demonstrated partial binding cross-reactivity to heterologous H1 and H3 strains, while CDP-N1 induced antibodies with cross-reactive potential to N2. These preliminary findings suggest that iBoost may enhance both the magnitude and quality of humoral responses, supporting its potential as a platform to improve the breadth and kinetics of antibody induction. However, further studies incorporating functional and in-vivo challenge assays will be required to confirm protective efficacy and validate the translational potential of this approach.
No takes yet. Share an insight, caveat, or question.
Myburgh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: